Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat
Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020), an innovative and selective matrix metalloproteinase-12 (MMP-12) inhibitor. Conducted in Australia, the trial aimed to assess the safety, tolerability, and pharmacokinetics (PK) of ascending doses of linvemastat in healthy volunteers. The study marks a significant milestone in […]